Quebec court refuses to authorize class action prompted by voluntary withdrawal of a drug
For the first time, a Quebec court has refused to authorize a class action proposed after a drug manufacturer announced a voluntary withdrawal. The proposed class action concerned sibutramine, a weight-loss drug for obese patients. From 2000 to 2010, sibutramine was manufactured by Abbott Laboratories and marketed in Canada as the patent medicine Meridia®. Apotex also marketed a generic version, Apo-Sibutramine, in 2010. Both companies voluntarily withdrew the drug in October 2010 at Health Canada’s recommendation, after a study linked sibutramine with increased risk of heart attack and stroke in patients with a history of cardiovascular problems. The proposed class action was commenced four days later. The Quebec Superior Court held that the plaintiff had no cause of action against Apotex, and had alleged insufficient facts to warrant authorizing the class action against Abbott.

